Artificial intelligence can do a lot, and its untapped potential is immensely vast. In a groundbreaking development, AI has created the first dose of a drug that was just delivered to its first patient.
According to a biotechnology company called Insilico Medicine from Hong Kong, human patients began receiving the drug INS018_055, an anti-fibrotic small molecule inhibitor.
According to the company, the drug was found and designed with generative artificial intelligence. Before it was administered to humans, the drug passed through two phases of trials.
"With demonstrated potential against both fibrosis and inflammation, INS018_055 could offer another option for patients worldwide," said Feng Ren, co-CEO and chief scientific officer of Insilico Medicine in a statement.
Such anti-fibrotic drugs are used to prevent the build up of abnormal amounts of fibrous tissue that sometimes can grow in organs. The drug in question, INS018_055, is being tested to treat idiopathic pulmonary fibrosis, a scarring lung disease.
The drug was developed using Pharma.AI that has been in development since 2020. Currently, the drug is being studied as part of a randomised, double-blind, placebo-controlled trial.
Also read:?New AI Chatbot Intends To Outsmart Scammers And Waste Their Time
Patients are being given the drug orally for a 12-week period. The company will recruit 60 subjects with idiopathic pulmonary fibrosis to test the drug across 40 sites in the United States and China.
Also read:?New AI Tool Helps Unlock Secrets Of The Past By Translating Age-Old Cuneiform
"Initiating Phase II trials with this novel inhibitor for IPF represents a major milestone for deep generative reinforcement learning in drug discovery," said Alex Zhavoronkov, founder and co-CEO of Insilico Medicine, in a statement. "We will explore the efficacy for patients of AI-discovered and designed treatments in clinical trials, which is a true validation of our generative AI platform."
What do you think about the potential of AI in the field of medicine? Let us know in the comments below.?For more in the world of?technology?and?science, keep reading?Indiatimes.com.